Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis.

Coleman, C I; Bunz, T J; Eriksson, D; Meinecke, A-K; Sood, N A

Coleman, C I; Bunz, T J; Eriksson, D; Meinecke, A-K; Sood, N A.

Affiliation

Coleman CI; University of Connecticut School of Pharmacy, Storrs, CT.
Bunz TJ; Hartford Hospital, Hartford, CT.
Eriksson D; New England Health Analytics, LLC, Granby, CT, USA.
Meinecke AK; Bayer AG, Berlin, Germany.
Sood NA; Bayer AG, Berlin, Germany.

Diabet Med ; 35(8): 1105-1110, 2018 08.

Article in En | MEDLINE | ID: mdl-29663521

Subject(s)

Atrial Fibrillation/drug therapy; Diabetes Mellitus, Type 2/drug therapy; Diabetic Angiopathies/drug therapy; Rivaroxaban/therapeutic use; Warfarin/therapeutic use; Administrative Claims, Healthcare/statistics & numerical data; Aged; Atrial Fibrillation/complications; Atrial Fibrillation/epidemiology; Databases, Factual; Diabetes Mellitus, Type 2/complications; Diabetes Mellitus, Type 2/epidemiology; Diabetic Angiopathies/epidemiology; Female; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Warfarin / Diabetes Mellitus, Type 2 / Diabetic Angiopathies / Rivaroxaban Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Diabet Med Year: 2018 Document type: Article

Fulltext

XML

PubMed Links

Search on Google